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a b s t r a c t 
Miliary tuberculosis (TB), is a fatal form of disseminated TB characterized by tiny tubercles evident on 
gross pathology similar to innumerable millet seeds in size and appearance. Global HIV/AIDS pandemic 
and increasing use of immunosuppressive drugs have altered the epidemiology of miliary TB. Keeping 
in mind its protean manifestations, clinicians should have a low threshold for suspecting miliary TB. 
Careful physical examination should focus on identifying organ system involvement early, particularly 
TB meningitis, as this has therapeutic signiﬁcance. Fundus examination for detecting choroid tubercles 
can help in early diagnosis as their presence is pathognomonic of miliary TB. Imaging modalities help 
in recognizing the miliary pattern, deﬁne the extent of organ system involvement and facilitate image 
guided ﬁne-needle aspiration cytology or biopsy from various organ sites. Sputum or BAL ﬂuid examina- 
tion, pleural, pericardial, peritoneal ﬂuid and cerebrospinal ﬂuid studies, ﬁne needle aspiration cytology 
or biopsy of the lymph nodes, needle biopsy of the liver, bone marrow aspiration and biopsy, testing of 
body ﬂuids must be carried out. GeneXpert MTB/RIF, line probe assay, mycobacterial culture and drug- 
susceptibility testing must be carried out as appropriate and feasible. Treatment of miliary TB should be 
started at the earliest as this can be life saving. Response to ﬁrst-line anti-TB drugs is good. Screening 
and monitoring for complications like acute respiratory distress syndrome (ARDS), adverse drug reactions 
like drug-induced liver injury, drug-drug interactions, especially in patients co-infected with HIV/AIDS, 
are warranted. Sparse data are available from randomized controlled trials regarding optimum regimen 
and duration of anti-TB treatment. 
© 2016 Published by Elsevier Ltd. 
This is an open access article under the CC BY-NC-ND license 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ). 
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2. Introduction 
Tuberculosis (TB) is still a global public health problem in spite
f worldwide control effort s ( Table 1 ). As per the year 2014 es-
imates published in the Global Tuberculosis Report in 2015 [1] ,
n estimated 9.6 million people developed TB and 1.5 million died
rom the disease globally. Miliary TB is a fatal form of disseminated
B that results from a massive lymphohematogeneous dissemina-
ion from a Mycobacterium tuberculosis -laden focus [2–6] . Radiolog-
cally, the miliary pattern has been deﬁned as “a collection of tiny
iscrete pulmonary opacities that are generally uniform in size and
idespread in distribution, each of which measures 2 mm or less
n diameter” ( Fig. 1 ) [7] . 
Manget, is credited to have coined the term “miliary TB” in
700 [8] . He likened the tiny tubercles evident on gross patholog-cal examination to that of innumerable millet seeds in size and 
∗ Corresponding author. Tel.: + 91 11 26594415; fax: + 91 11 26589994. 
E-mail address: sksharma.aiims@gmail.com (S.K. Sharma). 
a  
i  
d  
d  
n  
ttp://dx.doi.org/10.1016/j.jctube.2016.03.003 
405-5794/© 2016 Published by Elsevier Ltd. This is an open access article under the CCppearance [ miliarius (Latin), translation: related to millet seed].
iliary TB is uniformly fatal if untreated. Due to varied clinical
anifestations, atypical radiographic ﬁndings and diﬃculties in es-
ablishing TB as the aetiological diagnosis, even today, miliary TB
emains a formidable diagnostic and therapeutic challenge [2,9] . In
his review, we have attempted to provide an overview regarding
he changing clinical picture of miliary TB and issues related to di-
gnosis and management. 
. Epidemiology 
.1. Methodological issues 
Reliable community-based epidemiological data are not avail-
ble on the prevalence of miliary TB. Some of the methodological
ssues include different denominators used, lack of a “gold stan-
ard” for diagnosis, variations in the choice and nature of invasive
iagnostic methods used for securing tissue to conﬁrm the diag-
osis among others. These issues should be kept in mind whileBY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ). 
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Table 1 
Epidemiology of tuberculosis 2014. 
Variable Estimate 
Incidence ∗ 133 (126–141) 
Prevalence ∗ 174 (158–190) 
Prevalence of HIV in incident TB cases ∗ 12 (11–13) 
Mortality ∗ 16 (13–18) 
HIV-positive TB mortality ∗ 5.3 (4.8–5.9) 
% of new cases with MDR-TB † 3.3 (2.2–4.4) 
% of retreatment cases with MDR-TB † 20 (14–27) 
Prevalence of XDR-TB among MDR-TB cases † 9.7 (7.4–12) 
Source: Ref. [1] . 
HIV = human immunodeﬁciency virus; TB = tuberculosis; MDR- 
TB = multidrug-resistant tuberculosis; XDR-TB = extensively drug-resistant 
tuberculosis. 
∗ Expressed as estimate (lower and upper bounds of 95% uncertainty lev- 
els)/10 0,0 0 0 population. 
† Numbers in parentheses indicate 95% conﬁdence intervals. 
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1  comparing and interpreting published epidemiological data on mil-
iary TB. 
2.2. Clinical and autopsy studies 
In various clinical studies among immunocompetent adults,
miliary TB accounts for less than 2% of all cases of TB and up to
20% of all extra-pulmonary TB (EPTB) cases [10–15] . In late HIV in-
fection, EPTB accounts for more than 50% of all cases of TB and
miliary TB is more frequently encountered [2–5] . In autopsy stud-
ies in adults, miliary TB was documented in a higher proportion
of patients, accounting for 0.3%–13.3% of all autopsies and 11.9%–
40.5% of all cases of TB [16–22] . 
2.3. Demographic trends 
Before the advent of anti-TB treatment, miliary TB was pre-
dominantly seen as a disease of infants and children [23,24] .
However, since the 1980s a changing epidemiological trend has
been observed and miliary TB is increasingly being recognized
in adults also. Two peaks are evident, one involving adoles-
cents, young adults and another later in life among elderly in-
dividuals [2–5,14,25–50] . This epidemiological change has been
thought to be due to global pandemic of human immunodeﬁciency
virus/acquired immunodeﬁciency syndrome (HIV/AIDS), increasing
occurrence of organ transplantation, use of immunosuppressive
drugs including anti-TNF- α, chronic hemodialysis program, among
others. Fig. 1. Chest radiograph (postero-anterior view) ( A ) and chest CT (lung window) ( B ) show
resemble the grains of pearl millet ( Pennisetum typhoides , bajra) (C). In pediatric as well as adult series [2–5,14,25–50] , male gen-
er seems to be more frequently affected by miliary TB. In some
dult series on miliary TB [14,22,34,39] a female preponderance
as been documented. A higher occurrence of miliary TB among
frican Americans has been observed in some of the earlier publi-
ations from the USA, though such a trend is not evident in later
tudies [2–5,29,40] . 
. Predisposing, associated conditions 
In patients with miliary TB, several predisposing or associ-
ted conditions have been documented. Some of these conditions
nclude childhood infections, malnutrition, HIV/AIDS, alcoholism,
hronic kidney disease, dialysis, post-gastrectomy status, organ
ransplantation, immunosuppressive drug use, connective tissue
isorders, pregnancy, postpartum, presence of an underlying ma-
ignancy, and silicosis [2–5] . Recent evidence has brought into fo-
us diabetes mellitus and tobacco smoking as newer emerging risk
actors in the causation of TB [9] . 
In addition to glucocorticoids, immunosuppressive, cytotoxic
rugs that are known to predispose to the development of mil-
ary TB, use of immunomodulatory biologicals has been reported
o cause fatal TB including miliary TB [51–54] . In a prospective
tudy among patients who received anti-tumor necrosis factor
anti-TNF) therapy [51] , disseminated and miliary TB accounted
or 27.5% of all TB cases and 44% of EPTB. In this study [51] ,
t was also observed that the rate of development of TB was
igher for adalimumab (136 events/10 0,0 0 0 person-years) and in-
iximab (144 events/10 0,0 0 0 person-years) than for etanercept (39
vents/10 0,0 0 0 person-years). In a prospective population-based
ational cohort study (2002–2011) from Sweden [53] the rate of
ncident TB in the general population and in a cohort of biological-
aïve and biological-exposed patients diagnosed with RA was esti-
ated. In comparison to the general population, patients with RA
ho were not exposed to biologicals had a four-fold increased risk
f TB (hazard ratio [HR] 4.2; 95% conﬁdence intervals [CI] 2.7–6.7),
hich did not decline over calendar time. Further, compared to
tanercept, the HRs for most recent exposure to adalimumab and
nﬂiximab were 3.1 (95% CI 0.8–12.5) and 2.7 (95% CI 0.7–10.9),
espectively; and the HR for etanercept compared with biological-
aïve RA was 1.7 (95% CI 0.6–4.6). In another recent study [54] that
nvestigated incidence of TB following anti-TNF therapy from Ko-
ea, a signiﬁcantly lower incidence of TB was observed in pa-
ients treated with etanercept (reference), compared with those
reated with inﬂiximab (incidence rate ratio [IRR] 6.8, 95% CI 3.74–
2.37) and adalimumab (IRR 3.45, 95% CI 1.82–6.55). A systematicing classical miliary pattern. The nodules ( < 2 mm) evident in miliary tuberculosis 
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b  eview and meta-analysis [55] of randomized controlled trials also
eported a higher risk of developing TB with adalimumab and in-
iximab than with etanercept. 
Several procedures and interventions, such as, ureteral catheter-
zation, extracorporeal shockwave lithotripsy, laser lithotripsy, car-
iac valve homograft replacement, have been implicated in the
ausation of miliary TB [56–60] . Further, the uncommon occur-
ence of miliary disease caused by intravesical bacille Calmette–
uerin (BCG) therapy for urinary bladder carcinoma has also been
ocumented [58] . 
. Immunopathogenesis 
Miliary TB is thought to result as a consequence of the in-
dequate effector T-cell (Teff) response in containing the tubercle
acillus [61–64] . In the context of immunopathogenesis of mil-
ary TB, Th1 cell activation, is central to protective immunity and
he Th2 cell activation represents impaired immunity. Evidence
s available suggesting that chemokine directed selective homing
f Th2 cells may play a critical role in the development of mil-
ary TB. In a susceptible host, immune responses skewed towards
h2 cross-inhibit protective responses, such as granuloma forma-
ion and this failure in limiting the disease activity at the local
ite favors dissemination. Miliary TB probably results from the Th2-
iased response occurring as a default pathway [63,64] . 
Recent data indicate that interleukin-4 (IL-4), with its ability
o downregulate inducible nitric oxide synthase (iNOS), toll-like
eceptor 2 (TLR2) and macrophage activation, determine whether
nfection with Mycobacterium tuberculosis becomes latent or pro-
ressive [2–5,61,62] . It is postulated that Mycobacterium tuberculo-
is either fails to evoke the protective response or drives the pro-
ective mechanisms and then deliberately ‘sabotage’ these leading
o progressive disease [61–64] . When the balance of homing of
egulator T (Treg) cells and Teff cells shifts towards the former,
here is a state of local immunosuppression leading to disease dis-
emination [2–5,63,64] . 
Molecular mechanisms thought to be responsible for disease
issemination and development of miliary TB have been de-
cribed [2–5,65–70] . These include impaired expansion of γ / δ T-
ells [65] , failure to generate adequate cell-mediated immunity
CMI) [66] , presence of human leucocyte antigen (HLA)-Bw15 [67] ,
LA-DRB1 ∗15/16, DRB1 ∗13, and DQB1 ∗0602 [68] , absence of HLA-
w6, HLA-DRB1 ∗10, and DQB1 ∗0501 [68] , impaired MHC class II
estricted target cell lysis, and over-exuberant lysis of target cell
acrophages [69] and LTA + 368 G/A polymorphisms [70] , among
thers. 
. Clinical presentation 
.1. Adults 
The clinical manifestations of miliary TB in adults are non-
peciﬁc and can be obscure till late in the disease. Classically,
ever with evening rise of temperature of several weeks duration,
norexia, weight loss, weakness and cough are evident [2–5] . Oc-
urrence of daily morning fever spikes [71] has also been reported.
hills and rigors, similar to that described in patients with malaria
nd bacteremia have been frequently described in adult patients
ith miliary TB [2–5] . Night sweats are common; sweat engraved
he patient’s silhouette on the bed, closely resembling a body’s
hadow ( damp shadow sign ) has been described in miliary TB [72] .
.1.2. Cryptic miliary TB 
In some patients, fever may be absent and the patients
ay present with a progressive wasting strongly mimicking aetastatic carcinoma. This presentation, termed “cryptic miliary
B” [73] is increasingly being reported in older individuals [23,24] .
.1.3. Organ system involvement 
Consistent with the systemic nature of the disease, patients
ith miliary TB present with symptoms and signs referred to
arious organ systems [2–5] . In the present era, imaging modali-
ies have made it possible to detect organ system involvement in
atients with miliary TB. Dry cough, scanty sputum and dyspnea
re frequently evident. Rarely, hemoptysis can occur. Skin lesions,
amely, eythematous macules and papules ( tuberculosis miliaria
utis ), may offer a valuable clue to the diagnosis [2–5] . Choroidal
ubercles are bilateral, pale, gray–white or yellowish lesions usu-
lly less than one quarter of the size of the optic disc and are
ocated within 2 cm of the optic nerve. When present, choroidal
ubercles are considered to be pathognomonic of miliary TB
2–5,45] . A systematic ophthalmoscopic examination is after mydi-
tric administration thus warranted in all patients with suspected
iliary TB ( Fig. 2 ). 
TB meningitis (TBM) has been described in 10%–30% adult pa-
ients with miliary TB [14,21,26–32,34,36,38,45,47,48] ; about one-
hird of patients presenting with TBM have underlying miliary TB
74] . Neurological involvement in adult patients with miliary TB in-
ludes TB meningitis with and without tuberculoma; and thoracic
ransverse myelopathy, among others [75] . Miliary TB presenting
ith overt adrenal insuﬃciency manifesting as Addison’s disease
t the time of initial presentation, or during anti-TB treatment has
lso been documented [76,77] . 
.2. Children 
Certain important differences have been observed in the clini-
al presentation of miliary TB in children compared to adults. Mil-
ary TB develops less frequently in children who have received the
CG vaccination [2–5] . In children with miliary TB, chills and night
weats, hemoptysis, productive cough are less common; periph-
ral lymphadenopathy and hepatosplenomegaly are more frequent
ompared with adults. TBM is more frequently seen in children
ith miliary TB (20%–40%) [2–5,26–44] compared to adults (15%–
0%) [14,21,26,27,29–32,34,36,42–48,50] . 
.3. Immunosuppressed individuals 
In patients with profound immunosuppression, such as those
o-infected with HIV, certain important differences are evident in
he presentation of miliary TB compared to immunocompetent in-
ividuals. Clinical presentation of miliary TB in persons with early
IV infection (CD4 + cell counts > 200 cells/mm 3 ), is similar to that
bserved in immunocompetent individuals. In late, advanced stage
f HIV infection miliary TB is seen more often [2–5,47,78–87] .
utaneous involvement, rarely seen in HIV-seronegative patients
ith miliary TB are more frequently seen in HIV-seropositive
nd other immunosuppressive patients [2–5,78,79–85] . These
nclude tiny papules or vesiculopapules, ( tuberculosis cutis miliaris
isseminata , tuberculosis cutis acuta generalisita) , and disseminated
uberculosis of the skin. Macular, pustular, or purpuric lesions,
ndurated ulcerating plaques ( Fig. 3 ), and subcutaneous abscesses
ave also been reported [86] . In late HIV-infection, intrathoracic
ymphadenopathy and tuberculin anergy are more common;
putum smears are seldom positive and blood culture may grow
ycobacterium tuberculosis [2–5,78–85,87] . 
.4. Rare manifestations and complications 
Several rare clinical manifestations and complications have
een reported in miliary TB. Sometimes, complications like acute
16 S.K. Sharma et al. / Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 3 (2016) 13–27 
Fig. 2. Ophthalmoscopic picture showing choroid tubercles (arrows). (For interpretation of the references to color in this ﬁgure, the reader is referred to the web version of 
this article.) 
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t  respiratory distress syndrome (ARDS) or myocarditis may in fact be
the initial presentation. Miliary TB presenting with ARDS, air-leak
syndromes, acute kidney injury (AKI), hepatic and gastrointestinal
manifestations is increasingly being reported from the emergency
department and intensive care unit (ICU). These rare manifesta-
tion may be a component of the multiorgan dysfunction syndrome
(MODS) due to TB or as a manifestation of immune reconstitution
inﬂammatory syndrome (IRIS) [88–94] . Atypical clinical presenta-
tion often delays the diagnosis and treatment. While ARDS may
develop anytime during the disease course, it is usually seen at the
time of initial presentation. Occurrence of ARDS has been observed
to be a poor prognostic marker [88–94] . 
Pneumothorax, which may sometimes be bilateral has been de-
scribed in miliary TB either at the time of initial presentation, dur-
ing the course of the disease or as a complication in TB-ARDS
patients receiving mechanical ventilation [2–5,95,96] . Pneumome-
diastinum with subcutaneous emphysema may develop due to
intrapulmonary rupture of alveoli and consequent air-leak that tra-
verses into the mediastinum after spreading along the vascular
sheath and this may be fatal [97] . 
AKI may occur due to direct renal parenchymal involvement
in patients with miliary TB [2–5,98] or as a manifestation of
IRIS [99] in HIV co-infected patients. Rarely, renal failure due ob-
structive uropathy has been described [78] . Other rare initial pre-
senting manifestations can be secondary hemophagocytic lympho-
histiocytosis (HLH), macrophage-activating syndrome (MAS), clini-
cal syndromes characterized by pancytopenia, hypertriglyceridemia
and/or hypoﬁbrinogenemia, evidence of hemophagocytosis in bonearrow, spleen or lymph nodes; other associated laboratory ab-
ormalities include hyperferritinemia and elevated blood levels of
actate dehydrogenase [100,101] . 
Miliary TB presenting with fulminant hepatic failure has been
eported [102] . An extrapulmonary focus discharging Mycobac-
erium tuberculosis into the portal circulation, resulting in hepatic
iliary TB is thought to be the underlying mechanism for this
resentation. Peritoneal involvement (ascites), intestinal involve-
ent (diarrhea or altered bowel habit) small intestinal perfora-
ions [33,103] have also been described. In patients with miliary
B, especially those co-infected with HIV, associated intrathoracic
nd intraabdominal lymphadenopathy involving portahepatis, pre-
nd paraaortic and mesenteric lymph nodes; retroperitoneal lym-
hadenopathy may be seen. 
Other important clinical lesions include Pott’s spine with or
ithout myelopathy, paraspinal cold abscess. Pelvic ascites, tubo-
varian masses, pyosalpinx can be seen in women with miliary TB
2–5] . 
Life-threatening cardiovascular complications have been doc-
mented in patients with miliary TB. These include myocarditis
104] , congestive heart failure [104] , native [105–107] and pros-
hetic valve [108] endocarditis, pericarditis, intracardiac mass [104] ,
ycotic aneurysm [109] , infection of a pacemaker pulse-generator
ocket [110] , infection of ventriculoatrial shunt causing miliary TB
111] and sudden cardiac death [112–114] among others. 
IRIS, reported in about one-third of patients co-infected with
IV and TB usually manifests within days to weeks of the ini-
iation of highly active antiretroviral therapy (HAART) [115,116] .
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Fig. 3. Clinical photograph of a HIV-seropositive patient who also had poorly con- 
trolled type 2 diabetes mellitus with miliary TB showing papulonodular cutaneous 
lesions over the face 
HIV = human immunodeﬁciency virus; TB = tuberculosis. 
Kind courtesy : Professor D.R. Reddy, Department of Dermatology, Venereology and 
Leprosy, Teerthanker Mahaveer Medical College & Research Centre , Moradabad, Ut- 
tar Pradesh, India. 
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Fig. 4. Algorithm for the diagnostic work-up of a patient with suspected miliary TB. 
The clinical and imaging diagnostic work-up should also aim at accurately assess- 
ing the extent of extrapulmonary involvement to facilitate monitoring and ensure 
adequate duration of treatment. All laboratory testing, especially, antituberculosis 
drug-susceptibility testing must be carried out in quality assured, periodically ac- 
credited laboratories. 
∗ Often used in children. 
† FNAC/excision biopsy. 
‡ Radiologically guided FNAC/biopsy. 
§ Mediastinoscopic/video-assisted thoracoscopic surgery, biopsy. 
|| Laparoscopic biopsy. 
Useful in advanced HIV infection. 
TB = tuberculosis; TST = tuberculin skin test; IGRA = interferon- γ release assays; 
HRCT = high resolution computed tomography; CECT = contrast enhanced com- 
puted tomography; MRI = magnetic resonance imaging; FNAC = ﬁne needle aspi- 
ration cytology; HIV = human immunodeﬁciency virus; AFB = acid-fast bacilli; L–
J = Lowenstein–Jensen medium; DST = drug-susceptibility testing; MGIT = mycobac- 
terial growth inhibitor tube; BACTEC = radiometric culture method; PCR = poly- 
merase chain reaction; GeneExpert MTB/RIF = GeneXpert MTB/RIF assay (Cepheid, 
Sunnyvale, CA); LPA = line probe assay 
Adapted and reproduced with permission from Sharma et al. [2] . nmasking and paradoxical IRIS are two subtypes. The clinical
ourse of IRIS can be brief or a prolonged course with multiple
ecurrent episodes has also been described. Miliary TB, sometimes
resenting with complications such as AKI, ARDS can occur as a
anifestation of IRIS [88,100,117] . In HIV-seronegative TB patients,
aradoxical worsening (deterioration) has been described, espe-
ially in lymph node TB and TB pleural effusion [78,79] . Fatal para-
oxical worsening of TB in a HIV-seronegative patient with gen-
ralized TB lymphadenopathy to cryptic miliary TB has been re-
orted [118] . 
. Diagnostic approach 
The diagnosis of miliary TB can be diﬃcult as the clinical man-
festations can be atypical and non-speciﬁc, the chest radiographs
o not always reveal the classical miliary pattern at the time of ini-
ial presentation. Therefore, a high index of clinical suspicion and
 systematic approach to diagnostic testing is required to establish
n early diagnosis of miliary TB ( Fig. 4 ) [2–5] . 
Patients with miliary TB should ideally be hospitalized for a
omplete diagnostic work-up. Patients presenting with dyspnea
hould be carefully evaluated for cardiac tamponade and ARDS.
linicians should have a low threshold for performing lumbar
uncture to document TB meningitis. 
Following criteria are useful for the diagnosis of miliary TB
n the clinical setting: (i) clinical presentation consistent with a
iagnosis of TB such as, pyrexia with evening rise of temperature,
18 S.K. Sharma et al. / Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 3 (2016) 13–27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 
Chest radiographic abnormalities in miliary TB. 
Classical presentation (50%) 
Miliary pattern 
Other pulmonary manifestations (10%–30%) 
Asymmetrical nodular pattern 
Coalescence of nodules 
Mottled appearance 
“Snow storm” appearance 
Ground glass appearance 
Air-space consolidation 
Associated ﬁndings ( < 5%) 
Pulmonary 
Parenchymal lesions and cavitation 
Segmental consolidation 
Thickening of interlobular septae 
Pleural 
Pleural effusion 
Empyema 
Pneumothroax 
Pneumomediastinum 
Others 
Intrathoracic lymphadenopathy 
Pericardial effusion 
Source: Refs. [2–5] . 
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a  weight loss, anorexia, tachycardia and night sweats of greater than
six weeks duration responding to anti-TB treatment; (ii) classical
miliary pattern on chest radiograph; (iii) bilateral diffuse reticulon-
odular lung lesions on a background of miliary shadows demon-
strable either on plain chest radiograph or high resolution com-
puted tomography (HRCT); and (iv) microbiological, histopatholog-
ical and/or molecular evidence of TB [45] . 
6.1. Tuberculin skin test and interferon-gamma release assays 
A positive tuberculin skin test (TST) or interferon-gamma re-
lease assays (IGRA) result only indicates infection with Mycobac-
terium tuberculosis and does not indicate active disease. Tuberculin
anergy is common in miliary TB and has ranged from 35%–74%
and 20%–70% in various pediatric [2–5,26,44] and adult series [29–
32,38–40,42,43] , respectively. In high burden TB countries, neither
IGRAs nor TST have been found to be adequate in accurately iden-
tifying persons who will beneﬁt from treatment of latent TB infec-
tion (LTBI) with high false positivity rates being reported for both
[119–122] . Further, even after completion of treatment, the PPD as
well as IGRAs will still remain positive. A policy statement issued
by the WHO [122] and the European Centre for Disease Prevention
and Control guidelines [121] discourage the use of IGRAs in prefer-
ence to TST, in areas where TB is highly endemic for the diagnosis
of pulmonary or extra-pulmonary TB. 
6.2. Laboratory testing 
A number of hematological and biochemical laboratory ab-
normalities have been described in miliary TB [2–5,21,26,27,28–
31,34,36,38–47] but their signiﬁcance is controversial. Dissem-
inated intravascular coagulation (DIC) [89,91] in patients with
miliary TB in the setting of ARDS and MODS is associated with
a high mortality. Immune mechanisms have been implicated to
cause bone marrow suppression and this could be the cause of
pancytopenia, hypoplastic anemia [2–5,123] . Hypercalcemia has
occasionally been documented in miliary TB [120–124] . Hypona-
tremia may indicate the presence of TB meningitis [40] and may
also be a predictor of mortality [45] in miliary TB. Several mech-
anisms, such as, an acquired disturbance of neurohypophyseal
function resulting in unregulated antidiuretic hormone (ADH)
release; an antidiuretic principle in the lung tissue affected by
TB that may either produce ADH or absorb an inappropriately
released hormone from the posterior pituitary [125–127] are
postulated mechanisms. 
6.3. Imaging studies 
Imaging modalities, such as, ultrasonography, computed to-
mography (CT), magnetic resonance imaging (MRI), 18 F labeled
2-deoxy-D-glucose (FDG) positron emission tomography-CT (FDG
PET-CT) have been used to deﬁne the extent of organ involvement
and evaluating response to treatment [2–5] . 
6.3.1. Chest radiograph 
Various chest radiographic abnormalities seen in miliary TB are
listed in Table 2 . Miliary pattern on chest radiograph [2–7] , the hall
mark of miliary TB, is seen in a majority of patients. The classical
miliary pattern on the chest radiograph represents summation of
densities of the tubercles that are perfectly aligned and imperfectly
aligned tubercles result in curvilinear densities and a reticulonodu-
lar pattern [128] . In about 10% of the cases, the nodules may be
greater than 3 mm in diameter [129] . Sometimes, well-deﬁned, lin-
ear, branching opacities ( tree-in-bud appearance ) may also be seenhen centrilobular bronchioles are dilated, or, are ﬁlled with mu-
us, ﬂuid or, pus and this pattern represents endobronchial spread-
ng of infection [2–5] . Rarely, ground glass opacities can occur due
o lymphatic obstruction or inﬁltration or acute lung injury [130] .
n some patients, predominance of lesions on one side may be evi-
ent. Sometimes, chest radiographs can be normal initially and the
ypical miliary pattern may evolve over the course of disease evo-
ution. Thus, periodic repeat chest radiographic examination should
e done in patients with suspected miliary TB during the course of
heir diagnostic evaluation [2–5,45] . 
.3.2. Ultrasonography 
Ultrasonography facilitates detection of free or loculated ascites,
ocal lesions in the liver or spleen, cold abscesses, mesenteric,
etroperitoneal or porta hepatis intraabdominal lymphadenopathy,
nvolvement of other abdominal organs and pleural effusion(s).
urther, diagnostic thoracic or abdominal paracentesis to procure
leural or peritoneal ﬂuid for diagnostic testing can be done under
ltrasonography guidance [2–5] . 
HRCT, thin-section multidetector row CT (MDCT) have facili-
ated the antemortem diagnosis of miliary TB. Classically, HRCT
eveals a mixture of both sharply and poorly deﬁned, less than
 mm nodules that are widely disseminated throughout the lungs
ssociated with diffuse reticulation [131,132] . The HRCT may reveal
lassical miliary pattern even when the chest radiograph looks ap-
arently normal [2–5,45] and also facilitates identiﬁcation of addi-
ional ﬁndings such as intrathoracic lymphadenopathy ( Fig. 5 ), cal-
iﬁcation, pleural and pericardial lesions [133] . 
Miliary pattern observed on HRCT may be diﬃcult to distin-
uish from that observed in miliary sarcoid and lymphangitis carci-
omatosa. The lesions of miliary TB are randomly distributed and
he lesions of miliary sarcoidosis are distributed along the bron-
hovascular bundle ( lymphangitic distribution ). Thus transbronchial
ung biopsy gives a higher diagnostic yield in miliary sarcoidosis
2–5] . On HRCT, air trapping has been described on HRCT both
t presentation and during follow-up period [133] and rupture of
hese areas of air trapping may result in air-leak syndromes in mil-
ary TB. The interlobular septal thickening or intralobular ﬁne net-
orking seen on HRCT in miliary TB reﬂects caseation necrosis in
he alveolar walls and interlobular septa. 
Abdominal CT ( Fig. 5 D) has been useful in identifying lesions
n the liver and spleen, intestine, mesentery, peritoneum, adrenals
nd lymph nodes, and also detects cold abscesses [2–5] . Unlike in
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Fig. 5. Chest radiograph (postero-anterior view) ( A ) and CT chest (lung window) ( B ) showing classical miliary pattern. CT chest (mediastinal window) ( C ) of the same patient 
also shows pre-vascular and mediastinal lymph nodes (arrows) CT (lung window). CT abdomen ( D ) of the same patient showing intrabdominal lymphadenopathy (asterisk). 
Bronchoalvelolar ﬂuid GeneXpert MTB/RIF detected Mycobacterium tuberculosis ; there was no rifampicin resistance. 
CT = computed tomography. 
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the chest, miliary lesions in the liver and spleen may appear as
iscrete hypodense lesions a few of which may be conﬂuent, some-
imes with irregular peripheral rim enhancement [134] . In female
atients with miliary TB, pelvic CT is useful to detect tubo-ovarian
asses, hydro and pyosalpinx, ﬂuid collection in the pouch of Dou-
las [2–5] . .3.3. Magnetic resonance imaging 
In patients with miliary TB, TBM, spinal TB, MRI of brain and
pine is very useful in documenting extent of neurological involve-
ent. As MRI does not use ionizing radiation, it offers the advan-
age that it can be repeated during follow-up if required [2–5] . 
20 S.K. Sharma et al. / Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 3 (2016) 13–27 
Fig. 6. Organ system involvement in military TB. PET maximum intensity projection image ( A ) showing abnormal tracer accumulation in the lung ﬁelds. Axial CT of the 
same patient showing randomly distributed miliary nodules in both lungs. Axial 18 FDG PET-CT fused image showing the FDG uptake in the nodules. 
PET = positron emission tomography; CT = computer tomography; 18 FDG-PET CT = 18 F labeled 2-deoxy-Dglucose positron emission tomography-computed tomography. 
Kind courtesy : Dr Madhavi Tripathy, Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India. 
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s6.3.4. Positron emission tomography 
In patients with extrapulmonary TB, FDG PET-CT appears to be
suited to deﬁne the extent and multiplicity of lesions at the time
of initial presentation and assessing the activity of lesions during
and at the end of anti-TB treatment ( Fig. 6 ). Little published data
are available on the 18 FDG PET-CT ﬁndings in patients with mil-
iary TB. Sharma et al [2] have reported that miliary as well as co-
alesced lesions can be evident on FDG PET-CT. The 18 FDG PET-MRI
is another potentially useful future imaging tool in miliary TB. As
compared with 18 FDG PET-CT, there is no risk of radiation expo-
sure with 18 FDG PET-MRI. The 18 FDG PET-CT and PET-MRI have po-
tential to further understanding the clinico-radiographic-functional
correlation in miliary TB and merit further study. 
6.3.5. Image guided radiological procedures 
Image guided radiological procedures such as ﬂuid aspiration,
ﬁne needle aspiration for cytological examination (FNAC) and
biopsy under CT or MRI guidance are useful for procuring tis-
sue/body ﬂuids for diagnostic testing. 
6.4. Sputum examination 
When available, sputum must be subjected to conventional
methods of smear, and mycobacterial culture examination. Theeader is referred to Section 6.12 . for details. Use of molecular
ethods in sputum testing is described under Section 6.15 . 
.5. Bronchoscopy 
Fibreoptic bronchoscopy, bronchoalveolar lavage (BAL) ﬂuid,
ronchoscopic aspirate, brushings, and transbronchial lung biopsy
TBLB) have all been used to conﬁrm the diagnosis of mil-
ary TB and may provide a diagnostic clue in up to 50% of
atients [27,36,38,43,45,135] . Further, endobronchial ultrasound
uided transbronchial needle aspiration (EBUS-TBNA) facilitates di-
gnostic sampling of subcarinal and mediastinal lymph nodes [2] . 
.6. Mediastinoscopy 
Mediastinoscopy, if available can be useful in obtaining tissue
amples from intrathoracic lymph nodes for diagnosis of miliary
B. 
.7. Video-assisted thoracoscopic surgery 
Video-assisted thoracoscopic surgery can facilitate diagnostic
ampling of pleura, intrathoracic lymph nodes and lung. 
S.K. Sharma et al. / Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 3 (2016) 13–27 21 
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Table 3 
Some causes of miliary pattern on the chest radiograph. 
Common causes Rare causes 
Infections ∗ Infections 
Tuberculosis Cryptococcosis 
Histoplasmosis Legionellosis 
Blastomycosis Melioidosis 
Coccidioidomycosis Tularaemia 
Mycoplasma pneumonia Psittacosis 
Nocardiosis Brucellosis 
Immunoinﬂammatory disorders ∗ Staphylococcus aureus bacteremia 
Sarcoidosis Toxoplasmosis 
Malignant Schistosomiasis 
Bronchoalveolar carcinoma Strongyloide stercoralis 
Carcinoma lung with hyperinfection 
lymphangitis carcinomatosa Malignant 
Metastatic carcinoma Bronchial carcinoid 
Tropical pulmonary eosinophilia Lymphoma 
Haemosiderosis in long standing Lymphomatoid granulomatosis 
rheumatic heart disease, mitral Occupational lung diseases 
stenosis 
Hypersensitivity pneumonitis 
Drug-induced interstitial lung disease 
(e.g., methotrexate, chrysotherapy, 
cyclophosphamide, nitrofurantoin, 
antidepressants) 
Source: Refs. [2–8] . .8. Echocardiography 
In the appropriate clinical setting, two-dimensional transtho-
acic echocardiography is useful in detecting pericardial effusion
nd myocardial involvement in miliary TB. 
.9. Laparascopy 
Laparascopy provides an opportunity to visualize the lesions in
atients with abdominal involvement and facilitates procurement
f biopsy material for diagnostic conﬁrmation [136] . 
.10. Bone marrow aspiration and biopsy 
Bone marrow aspiration and biopsy specimens should be sub-
ected to cytology, histopathology, culture, DST and molecular
ethods of diagnosis [2–5] . 
.11. Body ﬂuids and tissue examination 
Depending on the extent of organ system involvement, appro-
riate tissue and body ﬂuid samples must be obtained to conﬁrm
iagnosis. When imaging studies reveal focal lesions, image-guided
NAC or tru-cut biopsy can be carried out and the tissue thus pro-
ured should be subjected to histopathological, microbiological, or
olecular evaluation to conﬁrm the aetiological diagnosis. 
Bone marrow aspiration and needle biopsy obtained from the
osterior superior iliac spine have been found to be useful for
he diagnosis of miliary TB. Elevated serum alkaline phosphatase
evels suggest diffuse liver involvement and needle biopsy of the
iver can be useful in conﬁrming the diagnosis. Where applica-
le, pleural ﬂuid, pericardial ﬂuid, ascitic ﬂuid, CSF, urine, broncho-
copic secretions, blood and tissue biopsy specimens have all been
ested to conﬁrm the diagnosis of miliary TB [2–5,11,14,21,26,27,29–
2,34,36,38–40,42,47,48,50] . 
.12. Mycobacterial culture and drug-susceptibility testing 
Presently, liquid culture, solid culture on Lowenstein-
ensen medium and DST by phenotypic methods are the gold
tandard for mycobacterial culture and DST respectively. Rapid
ulture methods such as the BD BACTEC® 460 TB System (Becton,
ickinson; New Jersey) and the BD BACTEC® MGIT® 960 System
hat combines the advantages of BACTEC® with mycobacteria
rowth inhibitor tube (MGIT) (BD MGIT®, Becton, Dickinson; New
ersey), molecular methods (vide infra) may be useful for rapid
ST [2–5] . 
In patients with miliary TB, mycobacterial culture and drug-
usceptibility testing (DST) of sputum, body ﬂuids and tissue
pecimens must be carried out. DST for ﬁrst-line anti-TB drugs
FLDs), second-line anti-TB drugs (SLDs) should be carried out in
n accredited laboratory with external quality assurance can fa-
ilitate correct identiﬁcation of multidrug-resistant TB (MDR-TB),
re-extensively drug-resistant TB (pre-XDR-TB), extensively drug- 
esistant TB (XDR-TB) and facilitate appropriate management [9] . 
.13. Serodiagnostic methods 
The World Health Organization (WHO) policy statement on the
se of serodiagnostic tests strongly recommend that the currently
vailable commercial serodiagnostic tests should not be used for
he diagnosis of active pulmonary and extra-pulmonary TB disease
ncluding miliary TB [137] . .14. Adenosine deaminase 
When there is pleural effusion, ascites, elevated body ﬂuid
denosine deaminase (ADA) and interferon-gamma levels estima-
ion in ascitic ﬂuid, pleural ﬂuid point to TB as the aetiological
ause [138–143] . 
.15. Molecular methods 
Polymerase chain reaction (PCR) of CSF, tissue biopsy specimens
nd blood (especially in HIV-infected patients), has been used for
iagnostic conﬁrmation [78] . The PCR has been found to be most
seful when applied to clean specimens such as CSF where its sen-
itivity and speciﬁcity have been reported to be 0.5–0.9 and 1.0,
espectively [2–5,78] . 
Current evidence suggests that the GeneXpert MTB/RIF as-
ay (Cepheid, Sunnyvale, CA) appears to be the promising rapid
iagnostic test for patients with extrapulmonary TB. GeneXpert
TB/RIF utilizes a heminested real-time PCR assay to amplify
n Mycobacterium tuberculosis -speciﬁc sequence of the rpoB gene
hich is then probed with molecular beacons for mutations within
he rifampicin-resistance determining region. It can facilitate rapid
iagnosis from clinical specimens in 90 minutes time [144–147] . 
Line probe assays (LPAs), such as, the INNO-LiPA ® Rif. TB kit
Innogenetics NV, Gent, Belgium) and the GenoType ® MTBDR plus
ssay (Hain Lifescience GmbH, Nehren, Germany) have been found
o be useful for rapid screening of patients at risk for multidrug-
esistant TB (MDR-TB) [148,149] . 
LPA that can detect the tubercle bacillus and provide infor-
ation on isoniazid and rifampicin resistance (thereby identifying
DR-TB) for conﬁrmation of diagnosis in patients with suspected
iliary TB merits further study. 
.16. Pulmonary function, gas exchange abnormalities and 
ardiopulmonary exercise testing 
As in the case of other interstitial lung diseases (ILD) miliary
B is associated with typical abnormalities of pulmonary function.
he pulmonary function and gas exchange abnormalities may be
f a greater magnitude than might be expected from the chest ra-
22 S.K. Sharma et al. / Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 3 (2016) 13–27 
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t  diograph [150–153] . There is impairment of diffusion which can
be severe [154,155] , a mild reduction in ﬂow rates suggestive of
peripheral airways involvement [13] are evident. During the acute
stage, arterial hypoxemia due to widening of the alveolar-arterial
oxygen gradient and hypocapnia due to tachypnea can develop
[151] . Abnormal cardiopulmonary exercise performance including
lower maximum oxygen consumption, maximal work rate, anero-
bic threshold, peak minute ventilation, breathing reserve, and low
maximal heart rate have been reported in miliary TB [2–5,151,153] .
Other abnormalities include higher respiratory frequency, peak
minute ventilation at submaximal work, and high physiological
dead space/tidal volume and a demonstrable fall in oxygen satu-
ration (to 4% or more) with exercise. Following anti-TB treatment,
these abnormalities reversed in a majority of the patients, though
they were persisting in some of them [151,153] . 
7. Differential diagnosis 
Several conditions can present with a miliary pattern on the
chest radiograph or CT ( Table 3 ) and these conditions must be dif-
ferentiated from miliary TB by detailed diagnostic work-up. 
8. Treatment 
In patients with miliary TB, there are no published random-
ized controlled trials assessing the eﬃcacy of the standard World
Health Organization (WHO) treatment regimens used in national
TB control programs worldwide [156] . In various guidelines [156–
158] , miliary TB is classiﬁed as “pulmonary TB” in the program-
matic approach because of pulmonary involvement. This classiﬁca-
tion does not, however, truly reﬂect the systemic nature of miliary
TB. 
There is no consensus regarding the optimum duration of
treatment for miliary TB. Careful evaluation of extent of organTable 4 
Daily treatment regimens for “new” adult patients presumed or known to have drug-s
Variable Gu
ATS-CDC-IDSA (157) 
Year of publication 2003 
Intensive phase RHZE for 2 months 
Continuation phase RH for 4 months 
If TBM is present, RH for 7–10 months 
Total duration 6 months 
If TBM is present, 9–12 months 
Glucocorticoids Not routinely recommended for miliary TB. Strongly 
recommended if TBM, TB pericarditis are present. 
For TB pericarditis, glucocorticoid treatment is 
recommended for 11 weeks. 
Daily treatment with oral prednisone (60 mg/day, or the 
equivalent dose of prednisolone) is given for 4 weeks, 
followed by 30 mg/day for 4 weeks, 15 mg/day for 2 weeks, 
and ﬁnally 5 mg/day for week 11 (ﬁnal week). 
For TBM, glucorticoid treatment is recommended for 6 
weeks. Daily treatment with oral dexamethasone, 
12 mg/day, is given for 3 weeks followed by 6 mg/day for 
the next 3 weeks. 
Glucocorticoid treatment may be useful for treating 
respiratory failure (expert opinion) 
ATS = American Thoracic Society; CDC = Centers for Disease Control and Prevention
Health and Clinical Excellence; WHO = World Health Organization; TB = tuberculo
meningitis. 
∗ In populations with known or suspected high levels of isoniazid resistance, new TB
alternative to HR (weak/insuﬃcient evidence, expert opinion). ystem involvement, especially, for TBM and TB pericarditis is in-
icated before the initiation of anti-TB treatment as this can in-
uence the therapeutic decision. Most guidelines, such as, the
merican Thoracic Society (ATS), the Centers for Disease Control
nd Prevention (CDC), the Infectious Disease Society of America
IDSA) [157] and National Institute for Health and Clinical Excel-
ence (NICE) [158] guidelines from UK state that 6 months of treat-
ent is adequate for drug-susceptible miliary TB ( Table 4 ). How-
ver, the guidelines also suggest that when there is associated
BM, bone and joint TB the duration of treatment may have to
e longer. The evidence-based Indian extrapulmonary TB guide-
ines (INDEX-TB guidelines) that are shortly due to be published
re expected to provide clarity to these issues. 
While the guidelines provide a policy regarding treatment du-
ation, individual patients may require longer duration of treat-
ent. The patient depicted in Fig. 5 illustrates this point. This
atient with miliary TB also has mediastinal and intraabdominal
ymphadenopathy. As per the WHO guidelines [156] , this patient
ould have been notiﬁed as pulmonary TB in which case the ex-
rapulmonary lymph node component would have been under-
otiﬁed. From a programmatic management point of view, prac-
ical diﬃculties exist in extending the continuation phase beyond
he standard stipulated 6 months at the ﬁeld level in high burden
B countries. Sometimes, in patients with drug-susceptible miliary
B, in spite of the patient meticulously adhering to therapy, an ap-
ropriate treatment response may not be evident. The utility of
herapeutic drug monitoring in this scenario merits further study. 
For previously treated patients, the guidelines advocate that
pecimens for culture and DST should be obtained at or before
t the start of treatment. In settings where rapid molecular-based
ST results are available DST should be performed for at least
soniazid and rifampicin and, these results should be used to guide
he choice of regimen. It is important to accurately assess the ex-
ent of involvement clinically and radiologically failing which someusceptible miliary TB. 
ideline (reference) 
NICE (158) WHO (156) 
2006 2010 
RHZE for 2 months RHZE for 2 months 
RH for 4 months RH for 4 months ∗
If TBM is present, RH for 10 months If TBM is present, RH for 7–10 
months 
If bone and joint TB is present, 
RH for 7 months 
6 months 6 months 
If TBM is present, 12 months If TBM is present, 9–12 months 
If bone and joint TB is present, 
9 months 
Not routinely recommended for miliary 
TB. 
Not routinely recommended for 
miliary TB. 
Recommended if TBM, TB pericarditis 
are present. 
Recommended for TBM and TB 
pericarditis 
For TB pericarditis, glucocorticoid 
equivalent to prednisolone 60 mg/day, 
gradually withdrawn after 2–3 weeks 
of initiation is recommended. 
For TBM, glucocorticoid equivalent to 
prednisolone 20–40 mg if on 
rifampicin, otherwise 10–20 mg 
gradually withdrawn after 2–3 weeks 
of initiation is recommended. 
; IDSA = Infectious Diseases Society of America; NICE = National Institute for 
sis; R = rifampicin; H = isoniazid; Z = pyrazinamide; E = ethambutol; TBM = TB 
 patients may receive HRE as therapy in the continuation phase as an acceptable 
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once the liver functions normalize. There has been a lack of con- 
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T
d
Aatients, for e.g., those with undiagnosed TBM may receive sub-
ptimal treatment. While the standard duration of treatment may
e suﬃcient for most patients, each patient needs to be assessed
ndividually, and wherever indicated, treatment duration may have
o be extended [2–5] . 
.1. Monitoring for adverse drug reactions 
Patients with miliary TB receiving anti-TB treatment should
e carefully monitored for adverse drug reactions, especially,
nti-TB drug-induced liver injury (DILI). Asymptomatic rise in hep-
tic transaminases is common in patients with miliary TB and un-ig. 7. Algorithm for treatment of miliary TB. The anti-retroviral treatment recommendat
B = tuberculosis; HIV = human immunodeﬁciency virus; + = seropositive; −= seronegativ
rome; DILI = anti-TB drug-induced liver injury; EFV = efavirenz; NNRTI = non-nucleoside r
dapted and reproduced with permission from Sharma et al. [2] . ess deﬁnitive evidence of DILI is present [159–162] , anti-TB treat-
ent should not be withheld based on this evidence alone. In trop-
cal countries, acute viral hepatitis must be ruled out in patients
ho develop anti-TB DILI [163,164] . 
When patients with miliary TB develop true anti-TB DILI, the
otentially hepatotoxic drugs (rifampicin, isoniazid and pyrazi-
amide) should be stopped [161] . These patients should be treated
ith non-hepatotoxic anti-TB drugs, such as ethambutol, strepto-
ycin and a ﬂuoroquinolone, till the liver functions normalize. In
hese patients, it is usually possible to reintroduce the same hep-
totoxic drugs that have been implicated in the causation of DILIions in miliary TB patients co-infected with HIV are based on Refs. [167,168] . 
e; ART = antiretroviral treatment; IRIS = immune reconstitution inﬂammatory syn- 
everse transcriptase inhibitors. 
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Table 5 
Predictors of poor outcome in patients with miliary TB. 
Demographic parameters 
Increasing age 
Female gender 
Male gender 
Co-morbid/predisposing conditions 
Presence of any underlying co-morbid disease 
Presence of one or more predisposing conditions 
Clinical manifestations 
History of cough / night sweats / dyspnea / chills 
Altered mental status 
Meningismus 
Temperature > 39.3 °C 
Icterus 
Hepatomegaly 
Laboratory abnormalities 
Hyponatremia 
Hypoalbuminemia 
Elevated serum hepatic transaminase levels 
Elevated serum alkaline phosphatase 
Leucopenia 
Leucocytosis 
Lymphopenia 
Thrombocytopenia 
Others 
Presence of atypical chest radiographic patterns 
Treatment delay 
High nutritional risk score ∗
Source: Refs. [22–50,166] . 
∗ A four-point nutritional risk score is deﬁned ac- 
cording to the presence of four nutritional factors: 
low body mass index ( < 18.5 kg/m 2 ), hypoalbuminemia 
(serum albumin < 30 g/L), hypocholesterolemia (serum 
cholesterol < 2.33 mmol/L) and severe lymphocytopenia 
( < 7 ×10 5 cells/L). Each risk factor is assigned a value of 
1 if present or 0 if absent. Patients with three or four 
points were classiﬁed as having a high nutritional risk 
score (Ref. [169] ) sensus regarding the optimal sequence and dosage schedule for
reintroduction and these issues merit future study. 
8.2. Glucocorticoids 
Sparse published data are available speciﬁcally evaluating the
role of adjunct glucocorticoid treatment in patients with miliary TB
and the results have been conﬂicting. While a beneﬁcial response
was documented in some studies [165] , such a beneﬁt was not ev-
ident in others [166] . Presence of adrenal insuﬃciency is an ab-
solute indication for the administration adjunctive glucocorticoid
treatment. Many clinicians use adjunctive glucorticoid treatment
is considered to be beneﬁcial with TBM, large pericardial effusion,
IRIS, ARDS, and immune complex nephritis [2–5,167] . 
8.3. Antiretroviral drugs 
The eﬃcacy of standard anti-TB treatment regimens in the
treatment of miliary TB in HIV co-infected individuals has not
been studied in detail in real life, ﬁeld setting. Treatment of mil-
iary TB in patients co-infected with HIV requires careful consid-
eration of drug-drug interactions between anti-TB and antiretrovi-
ral drugs [167,168] . Rifampicin, by inducing the hepatic cytochrome
P450 pathway, can result in dangerously low levels of antiretroviral
agents. Rifabutin is preferred over rifampicin especially when pro-
tease inhibitors are used but is costly. Efavirenz is preferred over
nevirapine [167,168] . 
The current guidelines, such as the WHO guidelines
[156] should be followed regarding the timing of starting of
antiretroviral drugs, the choice of drugs and the timing of initia-
tion in relation to institution of anti-TB treatment. These details
are summarized in Fig. 7. 
8.4. Intensive care 
Intensive care, assisted mechanical ventilation, dialysis and
other interventions may be required for the management of
patients with miliary TB-ARDS and those admitted with MODS
[2–5,93,94] . 
8.5. Interventional radiological procedures 
Interventional radiological procedures like image-guided pigtail
catheter drainage for psoas abscess, coil or gel foam embolization
for treating hemoptysis are useful inthe management of complica-
tions of miliary TB [2–5] . 
8.6. Surgery 
Surgery is required to procure specimens for diagnostic testing
and for management of complications, such as, small bowel per-
foration, for relief of spinal cord compression with persistence or
recurrence of neurological deﬁcits, or instability of the spine [2–5] .
9. Mortality 
The mortality due to miliary TB is higher in adults (25%–30%)
compared to that observed in children (15%–20%) [29–32,36,38–
40,42,43] . Delayed initiation of speciﬁc anti-TB treatment appears
to be the most important factor responsible for mortality in miliary
TB. 
10. Predictors of poor outcome 
Several factors have been identiﬁed as predictors of poor
outcome in patients with miliary TB ( Table 5 ) [22–50,169] . Inatients with miliary TB-ARDS [91] , acute physiological and
hronic health evaluation (APACHE II) score greater than 18;
PACHE II score less than or equal to 18 in the presence of hypona-
raemia and arterial oxygen tension (PaO 2 ) to fraction of inspired
xygen (FIO 2 ) ratio less than or equal to 108.5 have been identiﬁed
o be predictors of death. 
1. Prevention 
Presently, the bacille Calmette–Guerin (BCG) vaccination is the
nly vaccine available for TB. The BCG is effective in reduc-
ng the incidence of miliary TB, especially in children [170,171] .
owever, BCG vaccine is not effective in individuals who have
TBI and should not be administered to immunosuppressed per-
ons. Targeted tuberculin testing and treatment is practiced in
ountries with low prevalence of TB such as the USA [172] but
nti-TB DILI is a potential risk with this intervention. The
uest for a more effective vaccine than BCG is still on [173,
74] . 
2. Future research 
Future research is required to assess the utility of newer di-
gnostic modalities, such as, GeneXpert MTB/RIF in the diagno-
is of miliary TB and to evolve a standardized diagnostic work-
p algorithm. Research should also focus on the optimal anti-TB
rug treatment regimens and duration in drug-sensitive as well as
rug-resistant miliary TB, including those with HIV/AIDS. Monitor-
ng schedules for recognition and treatment of anti-TB DILI, drug,
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 osage and duration of glucocorticoid use in patients with miliary
B also merit future study. 
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